ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ZVRA Zevra Therapeutics Inc

4.65
-0.02 (-0.43%)
May 31 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Zevra Therapeutics Inc ZVRA NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.02 -0.43% 4.65 19:00:00
Open Price Low Price High Price Close Price Previous Close
4.72 4.59 4.94 4.65 4.67
more quote information »

Recent News

Date Time Source Heading
5/15/202420:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/15/202420:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/15/202420:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/15/202420:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/15/202420:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/13/202415:47EDGAR2Form 8-K - Current report
5/09/202415:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/09/202406:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
5/08/202406:54EDGAR2Form 8-K - Current report
5/08/202406:00GLOBEZevra Therapeutics Reports First Quarter 2024 Financial..
5/01/202406:30GLOBEZevra Therapeutics to Report First Quarter 2024 Results on..
4/29/202406:30GLOBEZevra Therapeutics’ President and Chief Executive Officer..
4/15/202416:01GLOBEZevra Therapeutics Presents New Data on the Long-Term Safety..
4/10/202406:30GLOBEZevra Therapeutics Refinances Existing Debt with up to $100M..
3/28/202415:32GLOBEZevra Therapeutics Reports Fourth Quarter and Full Year 2023..
3/28/202406:42IHMARKETNEWSUS Stock Futures Stable in Pre-Market On Path for..
3/26/202415:30GLOBEZevra Therapeutics Announces Top-Line Data from the Phase 2..
3/25/202415:30GLOBEZevra Therapeutics to Present at the 23rd Annual Needham..
3/18/202406:30GLOBEZevra Therapeutics to Report 2023 Fourth Quarter and Full..
3/05/202406:34EDGAR2Form 8-K - Current report
3/04/202407:24EDGAR2Form 8-K - Current report
3/04/202406:30GLOBEZevra Therapeutics Provides FDA Update on the PDUFA Action..
2/28/202406:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
2/14/202415:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/06/202406:30GLOBEZevra Therapeutics to Present at the Oppenheimer 34th Annual..
2/02/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202419:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202406:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
1/23/202406:37EDGAR2Form 8-K - Current report
1/23/202406:30GLOBEZevra Therapeutics Appoints Experienced Biopharma Executive..
1/11/202415:50DJNXoma to Make $1 Million Milestone Payment to LadRx After FDA..
1/08/202407:03EDGAR2Form 8-K - Current report
1/08/202406:30GLOBEZevra Therapeutics Receives FDA Acceptance of Resubmission..
1/04/202407:55GLOBEZevra Therapeutics Appoints Global Medical Leader, Adrian..
12/27/202307:24DJNZevra Therapeutics Refiles Arimoclomol Application With FDA
12/27/202306:48EDGAR2Form 8-K - Current report
12/27/202306:30GLOBEZevra Therapeutics Announces Resubmission of Arimoclomol New..
11/20/202306:36EDGAR2Form 8-K - Current report
11/20/202306:30GLOBEZevra Therapeutics Completes Acquisition of Acer..
11/07/202316:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202306:25EDGAR2Form 8-K - Current report
11/07/202306:00GLOBEZevra Therapeutics Reports Corporate Updates and Third..
10/31/202306:30GLOBEZevra Therapeutics to Report Third Quarter 2023 Results on..
10/30/202315:42EDGAR2Form 425 - Prospectuses and communications, business..
10/30/202307:25EDGAR2Form 8-K - Current report